|
1
|
Torre LA, Bray F, Siegel RL, Ferlay J,
Lortet-Tieulent J and Jemal A: Global cancer statistics, 2012. CA
Cancer J Clin. 65:87–108. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Carr BI: Hepatocellular carcinoma: Current
management and future trends. Gastroenterology. 127:S218–S224.
2004. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Thorgeirsson SS and Grisham JW: Molecular
pathogenesis of human hepatocellular carcinoma. Nat Genet.
31:339–346. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Garzon R, Calin GA and Croce CM: MicroRNAs
in Cancer. Annu Rev Med. 60:167–179. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Murakami Y, Yasuda T, Saigo K, Urashima T,
Toyoda H, Okanoue T and Shimotohno K: Comprehensive analysis of
microRNA expression patterns in hepatocellular carcinoma and
non-tumorous tissues. Oncogene. 25:2537–2545. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Calin GA and Croce CM: MicroRNA signatures
in human cancers. Nat Rev Cancer. 6:857–866. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Li T, Yin J, Yuan L, Wang S, Yang L, Du X
and Lu J: Downregulation of microRNA-139 is associated with
hepatocellular carcinoma risk and short-term survival. Oncol Rep.
31:1699–1706. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Gu W, Li X and Wang J: miR-139 regulates
the proliferation and invasion of hepatocellular carcinoma through
the WNT/TCF-4 pathway. Oncol Rep. 31:397–404. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Hua S, Lei L, Deng L, Weng X, Liu C, Qi X,
Wang S, Zhang D, Zou X, Cao C, et al: miR-139-5p inhibits aerobic
glycolysis, cell proliferation, migration, and invasion in
hepatocellular carcinoma via a reciprocal regulatory interaction
with ETS1. Oncogene. 37:1624–1636. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Wong CC, Wong CM, Tung EK, Au SL, Lee JM,
Poon RT, Man K and Ng IO: The microRNA miR-139 suppresses
metastasis and progression of hepatocellular carcinoma by
down-regulating Rho-kinase 2. Gastroenterology. 140:322–331. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Wang L, Liu M, Zhu H, Rong W, Wu F, An S,
Liu F, Feng L, Wu J and Xu N: Identification of recurrence-related
serum microRNAs in hepatocellular carcinoma following hepatectomy.
Cancer Biol Ther. 16:1445–1452. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Qiu G, Lin Y, Zhang H and Wu D: miR-139-5p
inhibits epithelial-mesenchymal transition, migration and invasion
of hepatocellular carcinoma cells by targeting ZEB1 and ZEB2.
Biochem Biophys Res Commun. 463:315–321. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Lewis BP, Shih IH, Jones-Rhoades MW,
Bartel DP and Burge CB: Prediction of mammalian microRNA targets.
Cell. 115:787–798. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
John B, Enright AJ, Aravin A, Tuschl T,
Sander C and Marks DS: Human MicroRNA targets. PLoS Biol.
2:e3632004. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Wong N and Wang X: miRDB: An online
resource for microRNA target prediction and functional annotations.
Nucleic Acids Res. 43:D146–D152. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Croce CM: Causes and consequences of
microRNA dysregulation in cancer. Nat Rev Genet. 10:704–714. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Ritchie W, Rasko JE and Flamant S:
MicroRNA target prediction and validation. Adv Exp Med Biol.
774:39–53. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Volinia S, Calin GA, Liu CG, Ambs S,
Cimmino A, Petrocca F, Visone R, Iorio M, Roldo C, Ferracin M, et
al: A microRNA expression signature of human solid tumors defines
cancer gene targets. Proc Natl Acad Sci USA. 103:2257–2261. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Xie X, Tan W, Chen B, Huang X, Peng C, Yan
S, Yang L, Song C, Wang J, Zheng W, et al: Preoperative prediction
nomogram based on primary tumor miRNAs signature and
clinical-related features for axillary lymph node metastasis in
early-stage invasive breast cancer. Int J Cancer. 142:1901–1910.
2018. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Slattery ML, Lee FY, Pellatt AJ, Mullany
LE, Stevens JR, Samowitz WS, Wolff RK and Herrick JS: Infrequently
expressed miRNAs in colorectal cancer tissue and tumor molecular
phenotype. Mod Pathol. 30:1152–1169. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Mannavola F, Tucci M, Felici C, Stucci S
and Silvestris F: miRNAs in melanoma: A defined role in tumor
progression and metastasis. Exp Rev Clin Immunol. 12:79–89. 2016.
View Article : Google Scholar
|
|
23
|
Tian F, Li R, Chen Z, Shen Y, Lu J, Xie X
and Ge Q: Differentially expressed miRNAs in tumor, adjacent, and
normal tissues of lung adenocarcinoma. Biomed Res Int.
2016:14282712016. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Lu J, Getz G, Miska EA, Alvarez-Saavedra
E, Lamb J, Peck D, Sweet-Cordero A, Ebert BL, Mak RH, Ferrando AA,
et al: MicroRNA expression profiles classify human cancers. Nature.
435:834–838. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Wang L, Zhang X, Jia LT, Hu SJ, Zhao J,
Yang JD, Wen WH, Wang Z, Wang T, Zhao J, et al: c-Myc-mediated
epigenetic silencing of MicroRNA-101 contributes to dysregulation
of multiple pathways in hepatocellular carcinoma. Hepatology.
59:1850–1863. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Yu F, Yao H, Zhu P, Zhang X, Pan Q, Gong
C, Huang Y, Hu X, Su F, Lieberman J and Song E: let-7 regulates
self renewal and tumorigenicity of breast cancer cells. Cell.
131:1109–1123. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Shen K, Liang Q, Xu K, Cui D, Jiang L, Yin
P, Lu Y, Li Q and Liu J: MiR-139 inhibits invasion and metastasis
of colorectal cancer by targeting the type I insulin-like growth
factor receptor. Biochem Pharmacol. 84:320–330. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Krishnan K, Steptoe AL, Martin HC,
Pattabiraman DR, Nones K, Waddell N, Mariasegaram M, Simpson PT,
Lakhani SR, Vlassov A, et al: miR-139-5p is a regulator of
metastatic pathways in breast cancer. RNA. 19:1767–1780. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Ashour ME, Atteya R and El-Khamisy SF:
Topoisomerase-mediated chromosomal break repair: An emerging player
in many games. Nat Rev Cancer. 15:137–151. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Stewart L, Redinbo MR, Qiu X, Hol WG and
Champoux JJ: A model for the mechanism of human topoisomerase I.
Science. 279:1534–1541. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Pommier Y, Sun Y, Huang SN and Nitiss JL:
Roles of eukaryotic topoisomerases in transcription, replication
and genomic stability. Nat Rev Mol Cell Biol. 17:703–721. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Kim N, Huang SN, Williams JS, Li YC, Clark
AB, Cho JE, Kunkel TA, Pommier Y and Jinks-Robertson S: Mutagenic
processing of ribonucleotides in DNA by yeast topoisomerase I.
Science. 332:1561–1564. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Larsen AK and Gobert C: DNA topoisomerase
I in oncology: Dr Jekyll or Mr Hyde? Pathol Oncol Res. 5:171–178.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Rahman M, Jackson LK, Johnson WE, Li DY,
Bild AH and Piccolo SR: Alternative preprocessing of RNA-sequencing
data in the cancer genome atlas leads to improved analysis results.
Bioinformatics. 31:3666–3672. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Kümler I, Balslev E, Stenvang J, Brünner N
and Nielsen D: A phase II study of weekly irinotecan in patients
with locally advanced or metastatic HER2-negative breast cancer and
increased copy numbers of the topoisomerase 1 (TOP1) gene: A study
protocol. BMC Cancer. 15:782015. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Giovanella BC, Stehlin JS, Wall ME, Wani
MC, Nicholas AW, Liu LF, Silber R and Potmesil M: DNA topoisomerase
I-targeted chemotherapy of human colon cancer in xenografts.
Science. 246:1046–1048. 1989. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Li M and Liu Y: Topoisomerase I in human
disease pathogenesis and treatments. Genomics Proteomics
Bioinformatics. 14:166–171. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Pommier Y: Topoisomerase I inhibitors:
Camptothecins and beyond. Nat Rev Cancer. 6:789–802. 2006.
View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Sampson VB, Rong NH, Han J, Yang Q, Aris
V, Soteropoulos P, Petrelli NJ, Dunn SP and Krueger LJ: MicroRNA
let-7a down-regulates MYC and reverts MYC-induced growth in Burkitt
lymphoma cells. Cancer Res. 67:9762–9770. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Kumar MS, Erkeland SJ, Pester RE, Chen CY,
Ebert MS, Sharp PA and Jacks T: Suppression of non-small cell lung
tumor development by the let-7 microRNA family. Proc Natl Acad Sci
USA. 105:3903–3908. 2008. View Article : Google Scholar : PubMed/NCBI
|
